TOKYO, May 11, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today confirmed that the Court of Appeals for the Federal Circuit (CAFC) issued a Mandate that officially ends the CAFC appeal on patent infringement of LEXISCAN® (regadenoson injection) 0.4 mg/mL.

On May 3, 2023, the CAFC denied our petitions for rehearing and rehearing en banc of the CAFC’s December 30, 2022 Opinion that affirmed the U.S. District Court for the District of Delaware’s earlier decision that all asserted claims of the patents for LEXISCAN® are not infringed by Hospira, Inc.

Astellas has already reflected the impact from this decision in its financial forecast of the current fiscal year ending March 31, 2024.


Click below for a copy of the full press release


Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)